Balchem Corporation (BCPC)
NASDAQMaterialsChemicals - SpecialtySnapshot 2026-09-04
$171.61-0.08%
Close 2026-09-04 · 1-day change
NASDAQMaterialsChemicals - SpecialtySnapshot 2026-09-04
QuarterlyIQ Insights · BCPC
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 60.0% |
| Our one-year growth estimate | diamond | 7.6% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 52.4 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 40 industry peers
BCPC — credit agreement
Dated 2026-07-24
Entry into a Material Definitive Agreement. On July 24, 2026, Balchem Corporation, a Maryland corporation (“ Balchem ”), together with its foreign subsidiary Balchem B.V. (the “ Foreign Borrower ”), and certain domestic subsidiaries acting as guarantors (the “ Domestic Guarantors ”), entered into Amendment No. 1 (the “ Credit Agreement Amendment ”) to that certain Amended and Restated Credit Agreement, dated as of July 27, 2022 (the “ Credit Agreement ”) with JPMorgan Chase Bank, N.A. and JPM…
Why it matters: Changes in the credit agreement may affect Balchem's growth funding and strategy.
Watch forManagement says they can borrow more money. This will help their growth plans.
Also watch forManagement says there are issues with the new credit facility.
Why it matters: Earnings growth is key to maintaining investor confidence. A drop below 8% signals potential issues.
Worry ifQ2 2026 earnings growth below 8% compared to Q2 2025.
Less concerning ifQ2 2026 earnings growth above 8% compared to Q2 2025.
Why it matters: This number is important for checking how well the company runs. A drop may mean higher costs or lower sales.
Worry ifAdjusted EBITDA for Q2 2026 falls below $75 million.
Less concerning ifAdjusted EBITDA for Q2 2026 is $75 million or higher.
Why it matters: Revenue growth is crucial for future investments and market position. Slowing growth could signal challenges.
Worry ifRevenue growth below 8% in Q2 2026 compared to Q2 2025.
Less concerning ifRevenue growth above 8% in Q2 2026 compared to Q2 2025.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$77 on $10,000 · ±0.8% | How much price usually moves either way. |
| Bad day | $190 loss on $10,000 · 1.9% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $1,471 loss on $10,000 · 14.7% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Changes to the credit agreement can affect finances and growth plans. It shows capital management.
Watch forMore news about new growth plans may come from the increased credit facility.
Also watch forNo new projects or plans were announced after the credit agreement change.
Why it matters: A drop in gross profit margin may show higher costs or pricing issues. This impacts profits.
Worry ifGross profit margin falls below 35% in Q2 2026.
Less concerning ifGross profit margin stays above 35% in Q2 2026.
Why it matters: The materials sector is in a declining phase. A positive shift could benefit Balchem's growth outlook.
Watch forSector revenue growth turns positive after being negative for three years.
Also watch forSector revenue growth is still negative for another quarter.
Why it matters: Revenue growth is important for strong financial performance. It shows the company can grow.
Supportive ifQ3 revenue growth exceeds 10% year over year across all segments.
Worry ifQ3 revenue growth falls below 5% year over year across any segment.
Why it matters: Strong growth in net sales shows demand strength across all segments. It confirms management's growth strategy.
Supportive ifQ3 net sales growth exceeds 10% compared to Q3 of 2025.
Worry ifQ3 net sales growth is below 5% compared to Q3 of 2025.
Why it matters: This segment is a key driver of overall sales. Strong growth signals continued demand and effective strategy.
Supportive ifHuman Nutrition and Health segment revenue grows year over year by more than 10%.
Worry ifRevenue in the Human Nutrition and Health segment grows less than 5% year over year.
Why it matters: Adjusted EBITDA growth shows how well the company controls costs and boosts sales. This is an important sign of financial health.
Supportive ifAdjusted EBITDA increases by more than 10% year over year in Q3.
Worry ifAdjusted EBITDA growth is less than 5% year over year in Q3.
Why it matters: Free cash flow is crucial for funding growth and shareholder returns. Strong cash flow supports future investments.
Supportive ifFree cash flow exceeds $36 million in Q3.
Worry ifFree cash flow falls below $30 million in Q3.